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ABSTRACT
Objective. To evaluate the safety, tolerability, and efﬁcacy of ritonavir-boosted saquinavir 1000/100 mg twice daily
administered as a 500 mg ﬁlm-coated tablet in HIV-1-infected patients.
Methods. In this open-label, observational, 24-week survey conducted in 8 European countries, eligible HIV-
infected participants had been prescribed saquinavir/ritonavir in combination with other nonprotease inhibitor (PI)
antiretroviral agents as part of their HIV treatment regimen. The safety (grade 3 or 4 adverse events [AEs]),
tolerability (by an investigator-reported subjective rating system), and efﬁcacy (the percentage of participants with
<50 and <400 copies/mL HIV RNA and change from baseline in mean CD4+ cell count) were analyzed for the
overall study population and 7 subpopulations.
Results. The enrolled population included 2122 participants with 1908 completing the study; 44 (2.1%) withdrew
prematurely because of AEs, including 7 nontreatment-related deaths. There were 33 grade 3 or 4 AEs in 29 (1.4%)
participants; 7 AEs in 7 (0.3%) participants were considered treatment-related. Tolerability was reported to be “very
good” or “good” in 42% and 25% of participants, respectively. From baseline to week 24, the proportion of
participantswithHIVRNA<50 copies/mLincreasedfrom31.2%to47.6%andtheproportionwith<400 copies/mL
increased from 42.5% to 61.4%; the mean CD4+ cell count increased by 75 cells/mL. In the subpopulation analysis,
thegreatestefﬁcacybeneﬁtsoccurredinparticipantswhoweretreatment-naïveandinthosenothavingreceivedprior
PI therapy.
Conclusions. Treatment with the saquinavir 500 mg ﬁlm-coated tablet resulted in few grade 3 or 4 AEs and was well
tolerated and effective in a broad population of patients.
Key Words. Bioavailability; Ritonavir; Safety; Saquinavir; Tolerability
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.
interscience.wiley.com/authorresources/onlineopen.html
Introduction
T
he current U.S. [1] and European [2] guide-
lines for the initial treatment of human
immunodeﬁciency virus-1 (HIV-1)-infected pati-
ents recommend a regimen comprising 2 nu-
cleoside reverse transcriptase inhibitors (NRTIs)
and either a non-NRTI (NNRTI) or a protease
inhibitor (PI) as components of highly active anti-
retroviral therapy (HAART). This recommenda-
tionisbasedontheconsiderablereductioninHIV-
1-related morbidity and mortality since the
introduction of HAART [3–5] and in particular the
established efﬁcacy of PIs [1,2].
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®, Roche,
Inc) is a potent inhibitor of the HIV protease.
SQV has been approved by the European Medi-
cines Agency (EMEA) and the U.S. Food and
Drug Administration (FDA) for the treatment of
HIV infection in combination with other antiret-
roviral (ARV) agents. Available for oral adminis-
tration as a 200 mg hard gelatin capsule and a
500 mg ﬁlm-coated tablet [6], the 500 mg formu-
lation of SQV was developed to meet the need for
a more simpliﬁed ARV regimen with a reduced pill
burden. The 500 mg tablet and 200 mg capsule
offer equivalent bioavailability when administered
at doses of 1000 mg in combination with 100 mg
ritonavir (r) [7].
The efﬁcacy and safety of SQV/r 1000/100 mg
twice daily in combination with other ARVs have
been established in randomized clinical trials
[8–10]. However, while there are sufﬁcient data on
the treatment experience with the 200 mg SQV
capsule [8,9], experience with the use of SQV
500 mg tablets at the FDA- and EMEA-approved
dose is limited. The RAINBOW survey was initi-
ated to establish a large database of patients being
treated with the SQV 500 mg tablet at the
approved dose of 1000 mg in combination with r
100 mg twice daily to evaluate the safety proﬁle of
SQV/r and to assess treatment response, as mea-
sured by CD4+ cell counts and HIV viral loads, in
different patient subpopulations.
Methods
Study Design and Participants
This was an open-label, multicenter, phase 4
observational cohort study of HIV-infected
patients 18 years of age or older who had been
prescribed SQV/r 1000/100 mg twice daily with
NRTIs or NNRTIs as part of their HIV treatment
regimen. Excluded were patients who had received
previous treatment with SQV, who had simulta-
neous treatment with a PI other than SQV/r, who
had SQV/r at doses other than 1000/100 mg twice
daily, or who had nonadherence or poor compli-
ance to SQV/r that may have resulted in survey
data being deemed unreliable.
All participants were prescribed SQV 1000 as
2 ¥ 500 mg tablets twice daily. Survey data were
transcribed by the investigator from the patient
chart into an internet-based CRF system TRI@L-
IT. In cases in which participants were being
treated prior to enrollment, data were collected
both retrospectively and prospectively. Baseline
(before the ﬁrst dose of SQV/r) demographic char-
acteristics, hepatitis status, ARV history, labora-
tory data (including HIV RNA viral load, CD4+
count, and lipid levels), and clinical data were
recorded as well as year of HIV diagnosis and
current clinical disease stage and concomitant
medications including lipid-lowering agents. The
following data were collected from any visits
occurring up to 24 weeks after initiation of therapy
and were classiﬁed into the applicable time frame
(weeks 2–8, weeks 8–16, and weeks 20–30): HIV
RNA viral load, CD4+ cell count, dates of these
measures, assays used and lower limit of detection,
changes in concomitant medications including
changes in or introduction to lipid lowering
agents, unexpected and grade 3 and 4 adverse
events (AEs) and relationship to the study speciﬁc
medication, adherence information, and results of
hematology and biochemistry tests. Safety analyses
included the monitoring of changes in the follow-
ing laboratory parameters from baseline to last
available value: fasting lipids, bilirubin, glucose,
alanine transaminase, aspartate transaminase,
gamma-glutamyltransferase, and the percentage of
patients receiving lipid-lowering agents.
This study was conducted in accordance with
the Declaration of Helsinki in its revised edition
(Edinburgh, Scotland, 2000) and the guidelines
of current Good Clinical Practice. Local ethics
committees approved the study protocol and
documents relevant to their local regulatory re-
quirements prior to recruitment to the survey.
Written informed consent was obtained before any
observational data were collected for inclusion in
the survey. The right to request withdrawal of data
from the study was reserved at any time.
Analyses
The primary endpoint was the percentage of par-
ticipants with a grade 3 or 4 AE. Secondary end-
points included the percentage of participants with
<50 copies/mL and <400 copies/mL HIV RNA at
week 24 and the increase in mean CD4+ cell count
(cells/mL) from baseline to week 24. The efﬁcacy
analysis was based on the intent-to-treat popula-
tion. Overall tolerability and efﬁcacy (very good,
good, sufﬁcient, insufﬁcient, cannot be evaluated)
were assessed by the investigator at week 24. Ana-
lysis of safety and efﬁcacy was also undertaken
for the following subpopulations: treatment-naïve;
treatment-experienced but naïve to PIs; switched
from an alternative PI regimen (boosted lopinavir
[LPV/r], atazanavir [ATV/r] or fosamprenavir
[fAPV/r], or other PIs) due to toxicity; switched
from a prior non-PI regimen due to toxicity;
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ment at any time with a regimen that included a PI
(LPV/r, AZV/r, f/APV/r or other); and prior treat-
ment at any time with a regimen that did not
include a PI. Participants could be included in
more than one subpopulation. Note that these cat-
egories are not mutually exclusive, ie, a participant
could have received a prior treatment regimen that
included a PI as well as one that did not include a
PI. In addition, AEs were analyzed according to
gender, race/ethnicity, and country of residence.
Adverse events, reported diseases, and medications
were not coded but provided as listings of the
original terminology. Participants who discon-
tinued SQV/r treatment for any reason prior to
week 24 were included in the survey as treatment
failures.
A planned sample size of 2000 was selected as
sufﬁcient to gain representative information about
treatment experience. Descriptive summary statis-
tics were used in the analysis of this survey.
Results
Participant Disposition and Baseline Characteristics
A total of 119 investigators at centers in Austria,
Germany, Latvia, the Netherlands, Poland, Spain,
Switzerland, and the United Kingdom enrolled
2309 participants between May 3, 2005 and Sep-
tember 20, 2007. Of those enrolled, 2122 were
eligible for analysis and were included in the “all
participants” population (Figure 1). The 187 par-
ticipants not included in the analysis comprised:
(i) 11 German participants and 49 Polish partici-
pants, countries where the recruitment date was
extended beyond the original date of February 28,
2007; all participants recruited later than Febru-
ary 28, 2007 were excluded from the global analy-
sis but included in the local trial analyses; (ii) 21
Spanish participants and 23 participants from the
United Kingdom who were screened but ineli-
gible; and (iii) 80 German participants, one His-
panic participant, and two Polish participants
were included in the TRI@L-IT System but were
either not marked as authorized for analysis by
the investigator or excluded from analysis due to
other documentation failure. Patients not marked
as authorized for analysis were those for which
the investigator did not complete the online data
entry conﬁrmation.
The number of participants in each subpopula-
tionispresentedinTable 1.Intotal,78%weremen
with a majority (86%) being Caucasian; the mean
age was 43 years (Table 2). The median baseline
Figure 1 Participant disposition (“all
participants” population). Since the
recruitment phase of the survey was
extended in Germany and Poland,
participants from these countries who
were enrolled after February 28, 2007,
were not included in the global analy-
sis. In addition, no overall evaluation
of tolerability was available for those
from centers in Germany since they
were to be treated for longer than 24
weeks.
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and the median CD4+ cell count was 323 cells/mL.
The mean time since HIV diagnosis was 9 years
(range: 0–35 years). In the “all participants” popu-
lation, 31% had <50 copies/mL HIV RNA at base-
line compared to only 1.5% of the treatment-naïve
participants. Of the 2122 participants initially
enrolled, 1908 completed the study. Reasons for
premature withdrawal by subpopulation are shown
in Table 3. While the percentages of participants
withdrawn due to AEs (including nocturia, diar-
rhea, opportunistic infections, gastrointestinal
intolerability, myocardial infarction, death, pneu-
mococcemia, pregnancy, exanthema, vertigo,
hyperglycemia, cachexia, erectile dysfunction,
progression of lymphoma) were similar across
treatment groups, there was a disproportionate
percentage of participants lost to follow-up in the
treatment-naïve and HCV coinfection subgroups;
the reasons for this are not known.
Safety andTolerability
There were 33 reports of grade 3 or 4 AEs in 29
(1.4%) participants in the “all participants” popu-
lation (Table 4). Of these, 7 AEs reported in 7
participants (0.3%) were considered drug-related.
The percentages of participants with grade 3 or 4
AEs were similar across subpopulations. The per-
centage of participants with all AEs also was
similar across subpopulations (Table 5). There
were 6 serious AEs resulting in 5 deaths (0.2%), all
considered to be unrelated to treatment (3 due to
lymphoma, 1 due to toxoplasmosis/miliar tubercu-
losis, and 1 due to suicide).
The incidence of AEs was comparable between
men and women (6.7% vs. 7.4%) and across eth-
nicities. The highest occurrence of AEs by country
was reported for participants from Spain while the
lowest incidence (0.8%) was reported in those
from Poland. The investigators rated the tolerabil-
ity of SQV 500 mg as “very good” in 42% of
participants, “good” in 25%, “sufﬁcient” in 4%,
and “insufﬁcient” in less than 2% (Table 6). No
information about the evaluation of tolerability
was available for 463 (22%) participants because
they continued to be followed in the subcohorts
and subjective analysis was not carried out until the
subjects left the survey.
Mean increases from baseline to 24 weeks
in fasting plasma lipids are shown in Table 7.
Mean triglyceride levels increased from baseline
in the treatment-naïve and PI-naïve, treatment-
experienced groups but only in the PI-naïve,
treatment-experienced patient group were levels
elevated above the normal range. Mean total cho-
lesterol levels were elevated at baseline overall and
in those receiving a prior PI regimen as well as a
prior non-PI regimen and decreased slightly
during the study. The treatment-naïve, PI-naïve,
treatment-experienced, and toxicity switch from
prior non-PI regimen treatment groups all had
small increases from baseline in total cholesterol
levels to greater than acceptable levels. Mean base-
line fasting transaminase levels were elevated for
all subgroups, with most having reductions at week
24.
Mean fasting blood glucose levels were elevated
at baseline in three treatment groups (normal
range: 3.9–5.5 mmol/L): PI-naïve, treatment-
experienced (7.63 mmol/L; N = 114), toxicity
switch from prior non-PI regimen (8.04 mmol/L;
N = 102), and HCV coinfected (7.31 mmol/L;
N = 133). All had mean reductions resulting in
normal levels by 24 weeks: PI-naïve, treatment-
experienced (4.91 mmol/L; N = 93), toxicity
switch from prior non-PI regimen (4.87 mmol/L;
N = 88), and HCV co-infected (4.94 mmol/L;
N = 109).
Table 1 Subpopulations of participants initiating and completing the study, N (%)
Participants
initiating study*
Participants
completing study
All participants 2122 (100.0) 1908 (89.9)
Subpopulation
Treatment-naïve 413 (19.5) 360 (87.2)
PI-naïve but treatment-experienced 265 (12.5) 241 (90.9)
Toxicity switch from other PI regimen 161 (7.6) 151 (93.8)
Toxicity switch from prior non-PI regimen 201 (9.5) 183 (91.0)
HCV coinfection 287 (13.5) 254 (88.5)
Prior PI-containing regimen
† 1386 (65.3) 1252 (90.3)
Prior non-PI-containing regimen
† 1640 (77.3) 1485 (90.6)
*The percentage indicates the number of participants assigned to a particular subpopulation divided by the total study population. Since a participant may be
counted in more than one subpopulation, the total percentage of the subpopulations exceeds 100%.
†At any time during disease therapy.
HCV = hepatitis C virus; PI = protease inhibitor.
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The percentages of participants in the intent-
to-treat population with HIV RNA viral loads of
<50 and <400 copies/mL at baseline and at week
24 for each of the subpopulations are shown in
Figures 2A, B. In the overall population, 48% and
61% had <50 and <400 copies/mL at week 24,
respectively. Participants who were treatment-
naïve and PI-naïve achieved the greatest beneﬁts
with this regimen.
An increase in CD4+ cell count was also seen
during the survey period in 523/734 (71%) of par-
ticipants in the overall population having CD4+
cell count determinations (Table 8). The largest
increase in CD4+ cell count (138 cells/mL) and the
highest proportion of participants achieving an
increase in CD4+ cell count (92%) occurred in the
treatment-naïve subpopulation.
Discussion
This observational survey demonstrated that treat-
ment with the 500 mg ﬁlm-coated tablet of SQV
was well tolerated and effective in HIV-infected
participants. Not only was there a very low inci-
dence of grade 3 or 4 AEs, investigators rated the
tolerability of the regimen as “very good” or
“good” in 67% of their participants. A comparison
of the efﬁcacy across subpopulations showed that
the majority had a favorable response to treatment,
with those who were treatment- and PI-naïve
deriving the most beneﬁts. This is to be expected
since these subpopulations would be most suscep-
tible to a new regimen or to the addition of a new
class of agent.
There were certain limitations to this survey,
including its open-label design and its subjective
assessment of tolerability (which could have biased
the results) and the short duration of follow-up of
24 weeks. Still, the lack of blinding or of a control
regimen was unlikely to bias the laboratory-based
virologic efﬁcacy endpoints. Furthermore, it was
not possible to control for the variability in ARV
regimens and populations across study sites.
However,thevalueofthissurveyisits“real-world”
clinical setting, which increases the level of hetero-
Figure 2 Percentage of participants
in the intent-to-treat population with
(A) HIV-1 RNA <50 copies/mL and (B)
HIV-1 RNA <400 copies/mL at base-
line and at week 24 overall and by
subpopulation. HCV = hepatitis C
virus; PI = protease inhibitor.
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comitant ARV therapies. These results compare
favorably with those of a recent study that showed
that at 24 weeks, approximately 60% of trial non-
participants (those in prospective, population-
based cohort studies) achieved a viral load
<500 copies/mL when initiating treatment with
one of three PI-based regimens [11]. In contrast, at
24 weeks randomized controlled trial (RCT) par-
ticipantshadamuchhigherefﬁcacy(approximately
75%). The authors suggested that reasons for this
may include the strict inclusion criteria for RCT
participants, the trial setting (better outcome in
high-volume centers), and more frequent monitor-
ing or stronger adherence incentives. In addition, a
signiﬁcantly higher percentage of RCT partici-
pants were ARV-naïve at baseline compared to trial
nonparticipants (57% vs. 44%, respectively) [11].
The GEMINI study [10], an open-label, ran-
domized, 48-week study, established the noninfe-
rior efﬁcacy of using the SQV 500 mg tablet at
approved doses (SQV/r 1000/100 mg twice daily)
compared to LPV/r, both in combination with
once-daily tenofovir/emtricitabine, in treatment-
naïve HIV-infected participants. The proportions
of patients with HIV RNA levels <50 copies/mL
were 64.7% and 63.5% for the SQV/r and LPV/r
treatment groups, respectively (estimated differ-
ence in proportion for noninferiority: 1.14%, 96%
conﬁdence interval: -9.6, 11.9; P < 0.012); triglyc-
eride levels were signiﬁcantly higher in the LPV/r
groupatweek48.Thepresentstudyshowedthatin
both treatment-naïve and treatment-experienced
patients, oral SQV 500 mg was effective and well
tolerated with a more convenient and practical
dosing regimen than prior SQV-containing
regimens.
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